Emerging Applications of Liquid Biopsy and Circulating Tumor DNA in Early Detection and Monitoring of Pancreatic Cancer
Keywords:
Pancreatic Cancer, Liquid Biopsy, ctDNA, Early Detection, Cancer Monitoring, BiomarkersAbstract
Pancreatic cancer remains one of the deadliest malignancies due to late detection and limited treatment response. Liquid biopsy, especially circulating tumor DNA (ctDNA), offers a minimally invasive approach for early cancer detection, monitoring therapeutic response, and detecting relapse. This paper explores emerging applications of ctDNA in pancreatic cancer, reviews foundational research prior to 2022, and outlines current clinical and technological advancements, challenges, and future prospects.
References
[1] Cohen, J. D., et al. “Detection and Localization of Surgically Resectable Cancers with a Multi-Analyte Blood Test.” Science, vol. 359, no. 6378, 2018, pp. 926–930.
[2] Sausen, M., et al. “Clinical Implications of Genomic Alterations in the Tumor and Circulation of Pancreatic Cancer Patients.” Nature Communications, vol. 6, 2015.
[3] Bettegowda, C., et al. “Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies.” Science Translational Medicine, vol. 6, no. 224, 2014.
[4] Diaz, L. A., et al. “The Molecular Evolution of Acquired Resistance to Targeted EGFR Blockade in Colorectal Cancers.” Nature, vol. 486, 2012.
[5] Allenson, K., et al. “High Prevalence of Mutant KRAS in Circulating Exosome-Derived DNA from Early-Stage Pancreatic Cancer Patients.” Annals of Oncology, vol. 28, no. 4, 2017.
[6] Zill, O. A., et al. “The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.” Clinical Cancer Research, vol. 24, no. 15, 2018.
[7] Groot, V. P., et al. “Circulating Tumor DNA as a Biomarker for Diagnosis, Monitoring, and Prognosis in Pancreatic Cancer Patients.” Expert Review of Molecular Diagnostics, vol. 18, no. 10, 2018.
[8] Kahlert, C., and Kalluri, R. “Exosomes in Tumor Microenvironment Influence Cancer Progression and Metastasis.” Journal of Molecular Medicine, vol. 91, no. 4, 2013.
[9] Thierry, A. R., et al. “Clinical Validation of the Detection of KRAS and BRAF Mutations from Circulating Tumor DNA.” Nature Medicine, vol. 20, no. 4, 2014.
[10] Cohen, J. D., et al. “Combined Circulating Tumor DNA and Protein Biomarker-Based Blood Tests for Early Detection of Pancreatic Cancer.” PNAS, vol. 114, no. 38, 2017.
[11] Lee, J. S., et al. “Early Detection of Pancreatic Cancer Using cfDNA Methylation Markers.” Nature, vol. 576, 2019.
[12] Yu, J., et al. “Methylation Analysis of Circulating DNA for Pancreatic Cancer Detection.” Nature Communications, vol. 11, 2020.
[13] Phallen, J., et al. “Direct Detection of Early-Stage Cancers Using Circulating Tumor DNA.” Science Translational Medicine, vol. 9, no. 403, 2017.
[14] Heitzer, E., et al. “Circulating Tumor DNA as a Liquid Biopsy for Cancer.” Clinical Chemistry, vol. 61, no. 1, 2015.
[15] Gorgannezhad, L., et al. “Circulating Tumor DNA and Exosomes: From Detection to Therapy.” Biosensors and Bioelectronics, vol. 171, 2021.
[16] Zhang, Y., et al. “Targeting Circulating Tumor DNA in Pancreatic Cancer: A New Frontier.” Cancer Letters, vol. 518, 2021.
